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E-mail address: drvijay@mvdiabetes.com (V. ViswObjective: Monocyte Chemoattractant Protein-1 (MCP-1) is the strongest known chemotactic factor for
monocytes and is upregulated in diabetic nephropathy. So measuring urinary MCP-1 is of great signiﬁ-
cance in the diagnosis and intervention of early diabetic nephropathy. This study aims at determining
the levels of urinary MCP-1 (uMCP-1) at different stages of diabetic nephropathy and to see its correlation
with other parameters in Indian type2 diabetic subjects.
Materials and methods: A total of 64 (M:F; 40:24) type 2 diabetic subjects were divided into three groups
based on their renal function and were compared with non-diabetic controls (Group 1) n = 20 (M:F; 13:7).
The study groups were Group 2 (normoalbuminuria) n = 16, Group 3 (microalbuminuria) n = 23 and
Group 4 (macroalbuminuria) n = 25. Demographic, anthropometric and biochemical details were
recorded for all the subjects. Urinary MCP-1 levels were measured by using solid phase ELISA method.
Results: Mean levels of uMCP-1 in subjects with type 2 diabetes were signiﬁcantly higher than in controls
(p < 0.05). The levels of uMCP-1 in type 2 diabetic subjects increased gradually with deteriorating renal
function (p = 0.006). There was a signiﬁcant difference in urinary MCP-1 levels between Group 2 and
Group 1 (p < 0.001). Levels of uMCP-1 were signiﬁcantly higher in subjects with eGFR <60 ml/min com-
pared to eGFR >60 ml/min (p = 0.008). uMCP-1 levels correlated positively with uACR or uPCR (r = 0.551,
p < 0.0001), urea (r = 0.43, p < 0.0001) and creatinine (r = 0.478, p < 0.0001). A negative correlation
between uMCP-1 and eGFR (r = 0.338, p = 0.006) was noted.
Conclusion: Our study demonstrated that urinary MCP-1 levels increased gradually in type 2 diabetic
subjects with deteriorating renal function. It is signiﬁcantly associated with the other risk factors of dia-
betic nephropathy.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Diabetic nephropathy (DN) is one of the major complications of
diabetes mellitus and an important cause of increased mortality
and morbidity in diabetic patients. Both metabolic and hemody-
namic pathways play a crucial role in the progression of diabetic
nephropathy [1–3]. Several pathogenic mechanisms such as pres-
ence of glomerular hypertension, hyperglycemia, advanced glyca-
tion end products (AGE’s), activation of polyol pathway, high
activity of Protein Kinase C (PKC) and genetic susceptibility have
been found to be associated with the development and progression
of renal impairment related to diabetes [2].
Further, inﬁltration of the diseased kidneys by inﬂammatory
cells such as monocytes/macrophages is a hallmark of diabeticellitus. Published by Elsevier Ltd.
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Onephropathy. In DN, similar to the other glomerulonephropathies,
inﬁltration and activation of monocytes/macrophages in the mes-
angium plays an important role in glomerular injury. Macrophages
are thought to be playing a role in tubulo interstitial damage in DN
[4–7]. Recent evidence has highlighted the role of Monocyte Che-
moattractant Protein-1 (MCP-1) in DN and showed it as a major
factor inﬂuencing macrophage accumulation in renal disease.
MCP-1 is a member of the CC chemokine family which is produced
by endothelial cells, vascular smooth cells, keratinocytes, ﬁbro-
blasts, mesangial cells, tubular epithelial cells, lymphocytes and
monocytes/macrophages in response to a variety of proinﬂamma-
tory stimuli. It is the strongest known chemotactic factor for mono-
cytes and is upregulated in DN. Its expression has been identiﬁed
in kidney diseases which involve signiﬁcant inﬂammation
[2,8–11].
Current evidence from both human and animal studies suggests
that kidney MCP-1 production plays a critical role in the develop-
ment and progression of diabetic nephropathy. It was also sug-
gested that increased urinary MCP-1 expression appears earlier
than microalbuminuria in diabetes and several studies havepen access under CC BY-NC-ND license.
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renal diseases and diabetic nephropathy [5,11,12]. A recent study
in Chinese population, suggested that MCP-1 may be involved in
the development and progression of DN and showed the impor-
tance of measuring uMCP-1 [13].
It was also reported that blockade of the Renin Angiotensin sys-
tem using ACE inhibitors in type 2 diabetic patients with diabetic
nephropathy improved renal function by suppressing renal MCP-
1 levels [14]. So measuring urinary MCP-1 is of great signiﬁcance
in the diagnosis and intervention of early diabetic nephropathy.
There are no studies deﬁning the levels of urinary MCP-1 at differ-
ent stages of diabetic nephropathy from Indian population, hence
this study was planned with the aim of determining the levels of
urinary MCP-1 at different stages of diabetic nephropathy and its
correlation with other parameters in Indian type 2 diabetic
subjects.2. Research design and methods
2.1. Patients
This cross-sectional study comprised of 64 (M:F; 40:24) type 2
diabetic subjects and 20 (M:F; 13:7) non-diabetic control subjects
recruited from the out patient department of a tertiary care centre
in India. The control subjects were the attenders of the patients
who had participated in the study. History of diabetic ketoacidosis
or hypoglycemic coma in the past 3 months preceding the study,
presence of urinary tract infection, hepatic, other renal disease,
rheumatological, neoplastic, other endocrine diseases (except dia-
betes) was the exclusion criteria. Subjects on antihypertensives,
statins or using immunomodulatory medications were also
excluded from the study. Ethics committee of the institution
approved the study and all the subjects gave the written informed
consent prior the study began.
Group 1 consisted of non-diabetic control subjects (n = 20).
Type 2 diabetic subjects were divided into three groups based on
their renal status. The study groups were as follows: Group 2
(n = 16, M:F; 10:6) were the normoalbuminuric subjects having
urinary albumin by creatinine ratio (ACR) of <30 lg/mg creatinine
estimated by immunoturbidimetric method. Group 3 (n = 23; M:F;
13:10) were the microalbuminuric subjects having urinary albu-
min by creatinine ratio of 30–300 lg/mg creatinine and Group 4
(n = 25; M:F; 17:8) were the macroalbuminuric subjects having
massive proteinuria of expected protein excretion rate of
>500 mg/day with the presence of diabetic retinopathy. Glomeru-
lar Filtration Rate (eGFR) was calculated using Cockcroft and Gault
formula [15].2.2. Methods
Demographic and anthropometric details like age, weight,
height, duration of diabetes, duration of diabetic nephropathy were
recorded for all the study subjects. Family history of diabetes and
hypertension, smoking and alcohol consumption habits were ob-
tained from the medical records of the study subjects. Body Mass
Index (BMI) (kg/m2) was calculated using the standard formula.
Blood pressure was measured using a standard mercury sphygmo-
manometer. Blood samples were collected for the biochemical esti-
mations. Fasting and post-prandial samples were collected from
the known cases of diabetes and other subjects underwent a stan-
dard oral glucose tolerance test. All the biochemical investigations
were done by standard enzymatic procedures using Hitachi Auto-
analyser 917. Plasma glucose was measured by glucose oxidase
method. The diagnosis of diabetes was based on previous history
of diabetes or on the criteria of World Health Organization forthe classiﬁcation of glucose tolerance [16]. Glycosylated hemoglo-
bin (HbA1c %) was estimated by immunoturbidimetric method.
Fasting serum sample was used for the estimation of lipid proﬁle,
urea, creatinine and liver function test.
2.3. Urine MCP-1 assay
Freshly voided urine samples were collected and centrifuged at
2000 rpm/min for 10 min. Two millilitres supernatant was taken
for the estimation of uMCP-1 levels and stored at 20 C until
tested. Urinary MCP-1 levels were measured with a solid phase en-
zyme linked immunosorbent assay (Quantikine MCP-1 ELISA; R&D
Systems Inc., Minneapolis, USA). The coefﬁcient of mean variations
in the samples were <5%. The minimum detectable MCP-1 level
with this kit was less than 5 pg/ml. No signiﬁcant cross-reactivity
or interference was observed with this assay kit. uMCP-1 levels
were expressed as values corrected by the urinary creatinine con-
centration (mg of creatinine/dl).
2.4. Statistical analysis
All statistical analyses were performed using SPSS 10.0 Version
software (SPSS Inc., Illinois). Mean and standard deviation for con-
tinuous variables and percentages for categorical variables are re-
ported as relevant. Signiﬁcant differences between groups were
evaluated using the Student’s t-test, v2-test and ANOVA where
ever appropriate. The relationship between urinary MCP-1 and
the other variables of study subjects was tested by Pearson corre-
lation test. A p value of <0.05 was considered statistically
signiﬁcant.3. Results
Table 1 shows the demographic, anthropometric and hemody-
namic details of the study subjects. The study group (normoalbu-
minuric, microalbuminuric and proteinuric) subjects were older
than control group. Age and BMI was similar among the study sub-
jects in all the groups. Percentage of subjects with hypertension
was signiﬁcantly higher in microalbuminuric and proteinuric
groups compared to the normoalbuminuric group.
Table 2 shows the biochemical details of the study subjects.
Fasting and 2 h plasma glucose values and HbA1c % was similar
among the study groups. Mean levels of uMCP-1 in subjects with
type 2 diabetes were signiﬁcantly higher than those in the control
group (p < 0.05). The levels of uMCP-1 were higher in patients with
proteinuria as compared with normoalbuminuria (p < 0.05), micro-
albuminuria (p = 0.07) and healthy controls (p < 0.05). uMCP-1 lev-
els in Group 3 (microalbuminuric) were signiﬁcantly higher than
Group 1 (normoalbuminuric). There was a signiﬁcant difference
seen in the urinary MCP-1 levels between the normoalbuminuric
patients and controls (p < 0.001). The levels of uMCP-1 in type 2
diabetic subjects increased gradually with deteriorating renal sta-
tus (p = 0.006). As expected, the urea and creatinine levels were
higher in Group 4 compared to Groups 2 and 3. The lipid proﬁle
was similar among the study group subjects.
Table 3 shows the levels of uMCP-1 according to eGFR stage
wise as per KDOQI guidelines. The levels of uMCP-1 were signiﬁ-
cantly higher in subjects with eGFR value of <60 ml/min compared
to the subjects with eGFR values of >60 ml/min (p = 0.008). Serum
protein and serum albumin levels were signiﬁcantly different
among the study subjects according to eGFR stages (p = 0.001
and 0.029), respectively.
Among the study subjects, uMCP-1 levels correlated positively
with urinary ACR or PCR (protein to creatinine ratio) (r = 0.551,
p < 0.0001), serum urea (r = 0.43, p < 0.0001), serum creatinine
Table 2
Biochemical details of the study groups.










Fasting 4.7 ± 0.38 9.1 ± 3.7* 9.5 ± 2.7* 9.5 ± 4.1* 0.93
2 h 5.4 ± 0.5 14.6 ± 6.6* 12.9 ± 5.4* 13.6 ± 5.9* 0.67
HbA1c (%) 5.5 ± 0.28 8.6 ± 2.1* 9.2 ± 2.4* 9.0 ± 2.2* 0.71
uMCP-1/U. Cr (pg/mg) 9.8 ± 6.7 70.0 ± 65.3* 125 ± 93.4*,** 196 ± 163.1*
,** 0.006
Urea (lmol/l) 56.0 ± 10.4 60.2 ± 11.5 66.1 ± 24.4 119 ± 66.4**,# <0.0001
Sr. Crea (mmol/l) 52.8 ± 8.8 63.4 ± 15.8 76.6 ± 51 123.2 ± 85.4**
,# 0.006
T. Chol (mmol/l) 3.6 ± 0.5 4.6 ± 1.1 4.5 ± 1.3 4.5 ± 1.7 0.97
TG (mmol/l) 0.97 ± 0.37 1.93 ± 0.57 1.61 ± 0.80 2.07 ± 1.03 0.175
HDL-C (mmol/l) 1.13 ± 0.19 1.04 ± 0.20 1.09 ± 0.16 1.06 ± 0.29 0.788
LDL-C (mmol/l) 2.25 ± 0.48 2.99 ± 0.81 2.64 ± 0.84 2.62 ± 1.29 0.486
VLDL-C (mmol/l) 0.24 ± 0.08 0.96 ± 1.04 0.56 ± 0.4 0.80 ± 0.57 0.19
Values are mean ± SD.
* p < 0.05 vs Group 1.
** p < 0.05 vs Group 2.
# p < 0.05 vs Group 3.
Table 3
Biochemical details of the study subjects stage wise as per KDOQI guidelines.










Fasting 9.4 ± 3.4 10.6 ± 4.1 8.4 ± 2.3 5.9 ± 1.6 0.107
2 h 12.9 ± 5.7 16.4 ± 6.3 12.3 ± 4 7.5 ± 2.6 0.031
HbA1c (%) 8.8 ± 2.1 9.7 ± 2.4 8.5 ± 2.1 7.4 ± 0.8 0.23
uMCP-1/U. Cr (pg/mg) 110.7 ± 95.7 111 ± 67.7 226.8 ± 203 285.3 ± 221 0.008
Total protein (g/dl) 7.6 ± 0.6 7.2 ± 0.7 6.9 ± 0.8 6.2 ± 0.98 0.001
Serum albumin (g/dl) 4.2 ± 0.6 4.0 ± 0.48 3.8 ± 0.4 3.2 ± 0.29 0.029
T. Chol (mmol/l) 4.5 ± 1.2 4.7 ± 2.6 4 ± 1.4 5.7 ± 3.9 0.54
TG (mmol/l) 1.6 ± 0.7 1.9 ± 0.6 2.3 ± 1.3 2.1 ± 1.4 0.112
HDL-C (mmol/l) 1.13 ± 0.22 1.06 ± 0.24 0.93 ± 0.19 1.0 ± 0.15 0.079
LDL-C (mmol/l) 2.9 ± 0.9 2.6 ± 0.8 2.07 ± 0.8 3.6 ± 2.7 0.04
VLDL-C (mmol/l) 0.6 ± 0.7 0.9 ± 0.6 0.9 ± 0.6 1.2 ± 1.2 0.25
Values are mean ± SD.
Table 1
Demographic, anthropometric and hemodynamic details of the study groups.









M:F 13:7 10:6 13:10 17:8
Values are mean ± SD
Age (years) 34.4 ± 7.4 56.0 ± 11.0* 56.7 ± 10.8* 58.1 ± 11.5* 0.83
BMI (kg/m2) 24.0 ± 3.2 26.2 ± 4.1 28.0 ± 4.1* 26.6 ± 3.4* 0.26
Blood pressure (mmHg)
Systolic 114.0 ± 8.8 128.1 ± 11.1* 135.2 ± 13.4* 142.0 ± 18.9*,** 0.02
Diastolic 76.5 ± 6.7 79.4 ± 6.8 79.7 ± 6.7 82.2 ± 10.4 0.49
Dur DM (years) – 8.3 ± 7.3 10.0 ± 6.5 14.4 ± 6.7**
,# 0.013
Values are n (%); p value by Trend v2-test
HTN (%) – 5 (31.2) 15 (65.2) 21 (84) 0.003
FH of DM (%) 5 (25) 10 (62.5) 14 (60.9) 17 (68) 0.02
FH of HTN (%) 1 (5) 3 (13.7) 1 (4.3) 2 (8) 0.302
Smoking (%) – – 2 (8.7) 3 (12) 0.24
Alcohol (%) – 1 (6.3) 3 (13) 5 (20) 0.16
FH: family history; Dur DM: duration of diabetes.
* p < 0.05 vs Group 1.
** p < 0.05 vs Group 2.
# p < 0.05 vs Group 3.
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cholesterol (r = 0.273, p = 0.031). A negative correlation between
uMCP-1, eGFR (r = 0.338, p = 0.006) and HDL cholesterol
(r = 0.101, p = 0.43) was observed, but HDL cholesterol did not
show the statistical signiﬁcance. No signiﬁcant correlation was
found between urinary MCP-1 and age, BMI, duration of diabetes,
systolic and diastolic blood pressure, fasting and post-prandial glu-
cose values, HbA1c, total cholesterol and LDL cholesterol.4. Discussion
MCP-1 being a potent chemoattractant for monocytes, in-
creased glomerular expression of MCP-1 has been shown in several
glomerular diseases like diabetic nephropathy [17]. Recently, it has
been considered that diabetic nephropathy is an inﬂammatory dis-
ease [18]. Several studies have shown the associations of MCP-1
and renal injury among diabetic patients [5,11,19]. The levels of
uMCP-1 at different stages of DN among Indian type 2 diabetic sub-
jects are unknown. The current study ﬁndings showed that urinary
MCP-1 levels were increased in diabetic patients with proteinuria
compared to normoalbuminuric, microalbuminuric and control
subjects. Since the results of our study also showed the increasing
uMCP-1 levels with the progression of diabetic nephropathy,
inﬂammation can be considered as one of the major cause and
the increased levels indicates the extent of renal tubular damage.
Proteinuria itself may contribute to this damage thereby increasing
the expression of MCP-1 in renal tubule which further accelerate
the progression of DN. Similar ﬁndings were also observed in a
study conducted by Wang and Chen [13] which showed the
increasing urinary MCP-1 levels with deteriorating renal function
and found that uMCP-1 along with other risk factors is associated
with diabetic nephropathy.
The levels of uMCP-1 in normoalbuminuric group were signiﬁ-
cantly higher than those in healthy controls in our study. Similarly,
several studies reported that MCP-1 appeared earlier than urine
microalbumin [13,19,20]. The above ﬁndings of our study sug-
gested that some changes would have occurred early in the patho-
genesis of DN and MCP-1 may play an important role in the
progression and development of DN. In our study, uMCP-1 levels
correlated positively with urinary ACR or PCR, serum urea, serum
creatinine, triglycerides and VLDL cholesterol and negatively with
eGFR. Banba et al. [11] showed a highly signiﬁcant correlation be-
tween urinary levels of albumin and MCP-1 in diabetic subjects.
Similarly many studies showed that uMCP-1 levels positively cor-
related with albumin excretion rate [13,21]. Banba et al. also found
that urine levels but not serum levels of MCP-1 increased in accor-
dance with the extent of HbA1c and albuminuria [11] but in our
study we did not ﬁnd a signiﬁcant correlation with HbA1c and
more over we have not estimated MCP-1 in serum or plasma
samples.
Urinary MCP-1 levels inversely correlated with eGFR values in
our study. Our ﬁnding agrees with a recent report, which showed
an inverse correlation with eGFR [21]. The inverse correlation be-
tween MCP-1 and eGFR deﬁne the use of MCP-1 as a marker which
reﬂects the degree of kidney damage as estimated by glomerular
ﬁltration rate. Earlier reports [13,21,22] demonstrated a signiﬁcant
positive correlation between MCP-1 and glycemic control as indi-
cated by HbA1c levels but we did not ﬁnd a signiﬁcant correlation
either with glucose levels or with HbA1c in our study. This sug-
gests that hyperglycemia alone may not be sufﬁcient in determin-
ing increased MCP-1 expression and other factors may be involved
in the process which needs to be conﬁrmed in a large sample size.
There was no signiﬁcant correlation found between uMCP-1 and
age, duration of diabetes, BMI, systolic and diastolic blood pres-
sure, plasma glucose values, HbA1c, total cholesterol and LDL-cho-lesterol in our study. Another report also showed no correlation
between MCP-1 and age, BMI and duration of diabetes [21].
As far as treatment regimen is concerned, current treatment for
diabetic nephropathy includes glycemic control, use of an appro-
priate antihypertensive to keep blood pressure under control, use
of statins, diuretics and diet management but still many patients
progress rapidly with a deteriorating renal function. This proves
the role of inﬂammation in the pathogenesis of diabetic nephrop-
athy and also suggesting a need for additional immunotherapy as
an adjunct to the existing treatment regime. Some studies showed
[14,22] that intervention with ACE inhibitor or vitamin E supple-
ment decreased the level of MCP-1 and improved the renal func-
tion among diabetic subjects with diabetic nephropathy. The
limitations of our study are that being a cross-sectional study we
could not deﬁne if reducing MCP-1 levels improves renal function
in our population. We could not correlate urinary MCP-1 with ac-
tual measurement of 24 h protein which is a gold standard method.
However, a good correlation between ACR in a spot urine sample
and 24 h urine collection has been reported earlier [23]. Long term
clinical trials are required in determining the importance of reduc-
tion of MCP-1 level in improving renal status. The ﬁndings of our
study certainly lay a foundation to consider uMCP-1 as a new
and non-invasive diagnostic marker for early diagnosis of diabetic
nephropathy. It may be useful in evaluating and monitoring the re-
nal inﬂammation in patients with DN.
In conclusion, our study showed the increasing levels of uMCP-
1 in type 2 diabetic subjects with deteriorating renal function and
it is signiﬁcantly associated with the other risk factors of diabetic
nephropathy. The diagnostic value of urinary MCP-1 to assess the
effectiveness of therapy needs to be studied.References
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